Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Off-Label Discussion, But No Additions, For House User Fee Bill

Executive Summary

Several Republicans remain interested in expanding off-label communications, suggesting the issue could come up outside the user fee context, potentially as part of future drug pricing discussions.


Related Content

Pediatric Cancer Study Requirements Added To FDA User Fee Bill
Off-Label Communications: Near-Term ‘Seismic Shift’ In FDA Oversight Unlikely
FDA User Fee Bill: House Cmte. Makes Technical Changes, Adds Pricing Resolution
User Fee Bill Caught In Comey Firing Tidal Wave
Pediatric Study Timelines Could Change Under Senate PDUFA Bill
Gottlieb Q&A: Off-Label Communications And Right-To-Try
Off-Label Wish List: Industry Groups Want US FDA's Guidances To Do More
First Amendment Does Not Block Off-Label Enforcement Actions, FDA Reiterates
Industry Communications With Payors: US FDA Okays Info On Investigational Drugs
Off-Label Communication: When Does It Align With Approved Labeling?





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts